Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shan Dong Kexing Bioproducts Co (SHSE:688136) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shan Dong Kexing Bioproducts Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥5,017 Mil.
Shan Dong Kexing Bioproducts Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥271 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co EV-to-EBIT Related Terms
Shan Dong Kexing Bioproducts Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688136 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shan Dong Kexing Bioproducts Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shan Dong Kexing Bioproducts Co's EV-to-EBIT falls into.
Shan Dong Kexing Bioproducts Co's current Enterprise Value is ¥5,047 Mil.
Shan Dong Kexing Bioproducts Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥271 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co (SHSE:688136) has a EV-to-EBIT of 18.63 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. This is 36% below median its historical median of 29.11. According to the industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #199 out of 365 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Shan Dong Kexing Bioproducts Co's EV-to-EBIT too high?
Shan Dong Kexing Bioproducts Co's current EV-to-EBIT of 18.63 is 36% below median its 10-year median of 29.11. The Biotechnology industry median EV-to-EBIT is 15.79. Shan Dong Kexing Bioproducts Co's value of 18.63 is 18% above this industry median. Based on the distribution chart, Shan Dong Kexing Bioproducts Co ranks #199 out of 365 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shan Dong Kexing Bioproducts Co has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shan Dong Kexing Bioproducts Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #199 out of 365 companies for EV-to-EBIT. This places Shan Dong Kexing Bioproducts Co in the lower half of its industry. The industry median EV-to-EBIT is 15.79. Shan Dong Kexing Bioproducts Co's value of 18.63 is 18% above this benchmark. While the company's 10-year median is 29.11 vs. the industry median of 15.79, Shan Dong Kexing Bioproducts Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.79, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shan Dong Kexing Bioproducts Co's current EV-to-EBIT of 18.63 is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shan Dong Kexing Bioproducts Co's current EV-to-EBIT is 18.63, which is 36% below median its own 10-year median of 29.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shan Dong Kexing Bioproducts Co stock overvalued right now?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co (SHSE:688136) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.19, compared to a current price of ¥20.70 — trading 10.7% below its estimated fair value. The current EV-to-EBIT is 18.63, which is 36% below median its 10-year median of 29.11 and 18% above the Biotechnology industry median of 15.79. Shan Dong Kexing Bioproducts Co's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shan Dong Kexing Bioproducts Co (SHSE:688136), the current EV-to-EBIT is 18.63 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shan Dong Kexing Bioproducts Co (SHSE:688136) Overvalued in 2026?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co stock appears to be undervalued.
The current stock price of ¥20.70 is trading 10.7% below its estimated GF Value™ of ¥23.19.
GuruFocus considers Shan Dong Kexing Bioproducts Co to be Modestly Undervalued.
Key valuation signals for SHSE:688136:
EV-to-EBIT: 18.63 (36% below median its 10-year median of 29.11)
GF Value™: ¥23.19 vs. price of ¥20.70 (10.7% below fair value)
Industry Position: 18% above the Biotechnology median (#199 of 365)
No single metric tells the full story. See the SHSE:688136 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
46GF Score
Get the complete analysis for SHSE:688136
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688136 has been successfully added to your 
